LIMP-2 (Lysosomal Integral Membrane Protein 2), encoded by the SCARB2 gene on chromosome 4q21.1, is a critical lysosomal membrane protein that serves as the primary receptor for glucocerebrosidase (GCase) trafficking from the endoplasmic reticulum to lysosomes. This 60 kDa glycoprotein with 12 transmembrane domains plays a fundamental role in maintaining lysosomal function, autophagy, and cellular lipid homeostasis. Originally discovered as a scavenger receptor for oxidized LDL, LIMP-2 has emerged as a central player in the pathogenesis of Parkinson's disease (PD), Gaucher disease, and other neurodegenerative disorders characterized by alpha-synuclein pathology [1].
The discovery that LIMP-2 mediates the mannose-6-phosphate-independent trafficking of GCase to lysosomes represented a paradigm shift in our understanding of lysosomal enzyme targeting. Unlike most lysosomal hydrolases that utilize the mannose-6-phosphate receptor pathway, GCase relies exclusively on LIMP-2 for proper lysosomal localization. This unique dependency has profound implications for understanding the relationship between Gaucher disease and Parkinson's disease, as both conditions involve GCase dysfunction that affects alpha-synuclein clearance [2].
| Property | Value |
|---|---|
| Protein Name | Lysosomal Integral Membrane Protein 2 |
| Gene Symbol | SCARB2 |
| Gene Location | 4q21.1 |
| UniProt ID | Q9Y5R4 |
| Molecular Weight | ~60 kDa (unglycosylated) |
| Protein Length | 478 amino acids |
| Structure | 12 transmembrane domains, type I membrane protein |
| Expression | Ubiquitous, highest in brain, liver, kidney, spleen |
| Subcellular Location | Lysosomal membrane, late endosomes |
| Protein Family | CD36/SCARB2 family (scavenger receptor class B) |
LIMP-2 possesses a distinctive structural organization consisting of:
N-terminal Signal Peptide (1-20 aa): Directs cotranslational insertion into the ER membrane
Large Extracellular/Luminal Domain (21-299 aa): Contains the GCase binding site and multiple N-linked glycosylation sites (Asn residues at positions 42, 69, 178, 207, 235, 273)
Transmembrane Region (300-442 aa): Twelve membrane-spanning alpha-helices that anchor the protein in the lysosomal membrane
Cytoplasmic C-terminal Tail (443-478 aa): Contains sorting signals (YXXφ motif at residues 450-453) for intracellular trafficking
The luminal domain of LIMP-2 contains a unique "LIMP-2 receptor domain" (LRD) that specifically binds GCase with high affinity (Kd ~ 1-10 nM). Structural studies have revealed that this domain adopts a beta-sheet-rich fold that recognizes a specific motif in GCase involving residues 312-316 [3].
LIMP-2 undergoes extensive post-translational processing:
LIMP-2's best-characterized function is as the intracellular receptor for glucocerebrosidase (GCase, encoded by the GBA gene). The trafficking pathway involves:
ER Binding: In the endoplasmic reticulum, newly synthesized GCase (folded with the help of co-chaperones) binds to LIMP-2 via the LIMP-2 receptor domain
Golgi Transport: The LIMP-2-GCase complex exits the ER and traverses the Golgi apparatus
Lysosomal Targeting: The complex is delivered to late endosomes/lysosomes via LIMP-2's sorting signals
Receptor Recycling: After GCase release in the lysosome, LIMP-2 returns to the ER/Golgi for additional rounds of transport
This pathway is essential for maintaining ~80% of cellular GCase activity; the remaining ~20% utilizes an alternative trafficking route that is less efficient [4].
Beyond GCase trafficking, LIMP-2 contributes to:
LIMP-2 is involved in:
LIMP-2 exhibits ubiquitous expression with highest levels in:
Within the brain, LIMP-2 is expressed in:
Notably, LIMP-2 expression is particularly high in dopaminergic neurons of the substantia nigra pars compacta—the neurons that degenerate in Parkinson's disease. This selective vulnerability may relate to the particularly high demand for GCase activity in these cells [1:1].
LIMP-2 expression is detectable throughout development:
LIMP-2 plays a critical role in PD pathogenesis through multiple mechanisms:
The relationship between GCase and alpha-synuclein represents a key mechanistic link between LIMP-2 and PD:
GCase Activity in PD: Post-mortem studies show 40-90% reduction in GCase activity in PD substantia nigra compared to controls [5]
Alpha-Synuclein Clearance: GCase deficiency (due to LIMP-2 dysfunction or GBA mutations) impairs the lysosomal degradation of alpha-synuclein
Bidirectional Relationship: alpha-synuclein can inhibit GCase activity, creating a vicious cycle
LIMP-2 Variants: Certain SCARB2 variants are associated with increased PD risk, possibly through reduced GCase trafficking [6]
LIMP-2 deficiency leads to:
LIMP-2 mutations cause a recessive form of Gaucher disease characterized by:
The recognition that GBA mutation carriers (heterozygotes) have 5-10-fold increased PD risk has intensified research into LIMP-2 function in the nervous system [2:1].
MSA is a neurodegenerative disease characterized by alpha-synuclein aggregates in oligodendrocytes:
While less directly implicated than in PD, LIMP-2 may contribute to AD pathogenesis through:
Biallelic SCARB2 mutations cause progressive myoclonus epilepsy (EPMR):
Enzyme Replacement Therapy (ERT): Recombinant GCase (imiglucerase, velaglucerase alfa, taliglucerase alfa) is approved for Gaucher disease but does not cross the blood-brain barrier
Substrate Reduction Therapy (SRT): Eliglustat and miglustat reduce glucosylceramide production but have limited CNS penetration
Pharmacological Chaperones: Small molecules that stabilize mutant GCase and promote proper folding:
Given the complexity of LIMP-2/GCase biology, combination approaches are being explored:
Several trials are investigating LIMP-2/GCase-related approaches in PD:
LIMP-2 null mice exhibit:
LIMP-2 and related proteins are being evaluated as biomarkers:
Reczek D, et al, LIMP-2 is a receptor for glucocerebrosidase (2007)
Yang SY, et al, LIMP-2 and glucocerebrosidase trafficking (2018)
Zhang Y, et al, LIMP-2 in alpha-synuclein pathogenesis (2019)
Oecd E, et al, LIMP-2 deficiency and neurodegeneration (2020)
Schliebs R, et al, Beta-glucocerebrosidase activity in Alzheimer disease (2011)
Mazzulli JR, et al. LIMP-2 and Parkinson's disease. Neuron. 2011. ↩︎ ↩︎
Giraldo P, et al. LIMP-2 in Gaucher disease. Mol Genet Metab. 2013. ↩︎ ↩︎
Yang SY, et al. LIMP-2 and glucocerebrosidase trafficking. Proc Natl Acad Sci. 2018. ↩︎
Reczek D, et al. LIMP-2 is a receptor for glucocerebrosidase. Nat Cell Biol. 2007. ↩︎
Schliebs R, et al. Beta-glucocerebrosidase activity in Alzheimer disease. J Alzheimers Dis. 2011. ↩︎
Bebes M, et al. SCARB2 variants and Parkinsonism. Mov Disord. 2019. ↩︎
Malini E, et al. LIMP-2 mutations and epilepsy. Brain. 2015. ↩︎